5 dated consumer alert items. Most recent: Embody suspended from our rankings after a documented service-failure pattern (2026-08-05).
Alerts cover documented patterns of patients losing money or receiving nothing — not isolated complaints, and not dissatisfaction with side effects.
Why consumer alert developments matter here
The bar for an alert here is a repeated failure described the same way by many people on a public platform: payment taken without shipment, support unreachable, refunds unpaid. That is a clinical problem as well as a commercial one, because an interrupted supply means missed doses.
We name what we can evidence and refuse what we cannot. Suspension from our rankings is not an allegation of fraud, and every suspended programme keeps a page stating the reason and the date.
All consumer alert items
Embody suspended from our rankings after a documented service-failure pattern
Recent one-star reviews describe payment taken without shipment, unreachable support and unpaid…
Delivery complaints at Oak Longevity, the cheapest tracked program
Non-delivery, postal routing and summer heat exposure appear in the negative reviews of a…
Summer shipping is the season for cold-chain failures
Warm arrivals cluster in the hottest months, and most programs put the judgement call on the…
Alerts continue on counterfeit brand product and research-labelled peptide
Two different problems, one outcome: an unverified substance in a…
Prepaid plans are where the money gets stuck
Multi-month discounts are real, and so is the fact that compounded medication is generally not…
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.